We are seeking a curiosity driven, highly skilled scientific officer with considerable relevant experience to join the PP team. The types of analyses routinely performed include in vitro/ex vivo cell-based assays (e.g., for cell viability, proliferation, invasion, migration) to evaluate the efficacy of novel therapeutics (targeted and immunotherapies) as monotherapies or in combinations. Studies will also include discovery and validation of candidate predictive and pharmacodynamic biomarkers. As well as the use of established cancer cell lines, the role will involve derivation and characterisation of primary cell cultures, development and analysis of primary organoids and co-cultures. A range of molecular biology approaches will be used to function test hypotheses and credential therapy targets (e.g., CRISPR-Cas9 depletion/shRNA approaches and screens using these tools). Mid throughput drug screening will also be in remit.

This is an incredible opportunity to develop your career as a preclinical cancer pharmacologist within a multidisciplinary setting, adjacent to one of Europe’s largest cancer hospitals, surrounded by a wealth of expertise. You will be driven by the goal to support the development of novel therapies and biomarkers to optimise their clinical utility using patient relevant preclinical models and incisive technologies. You will want to uplift your existing skills sets and get involved in strategic decision making as we expand the PP team and seek to bring in new collaborations and additional funding. You will enjoy supporting early career scientists and derive satisfaction seeing them progress with their projects. You will be excited by the opportunity to work with our pharmacologists and biomarker specialists to gain a holistic view of how drug treatment perturbs cells from both the tumour and host.

This role affords an exciting opportunity to be part of a team testing the efficacy of novel therapeutics with parallel development of biomarkers to optimise their application in the clinic for the benefit of patients with cancer.